<DOC>
	<DOC>NCT00761592</DOC>
	<brief_summary>This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm. Blepharospasm is characterised by excessive contraction of the muscles around the eye and can lead to repetitive blinking or sustained closure of the eyelids.</brief_summary>
	<brief_title>Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm</brief_title>
	<detailed_description />
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Diagnosed with benign essential blepharospasm Received ≥20U/eye of BOTOX® for at least one visit prior to study entry and required, in the investigators opinion, the same dose at the study injection visit. Combined Jankovic Rating Score of &gt;2 Female subjects who were pregnant, breastfeeding, or who were of childbirth potential and not practicing birth control. Profound atrophy of the muscles in the target area(s) of injection. Myasthenia Gravis, LambertEaton Syndrome, Amyotrophic Lateral Sclerosis or any other disease that might interfere with neuromuscular function. Known significantly impaired renal and/or hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>